Angion Biomedica Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANGN research report →
Companywww.angion.com
Angion Biomedica Corp. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung.
- CEO
- Jay R. Venkatesan
- IPO
- 2021
- Employees
- 3
- HQ
- Uniondale, NY, US
Price Chart
Valuation
- Market Cap
- $30.11M
- P/E
- -0.45
- P/S
- 0.00
- P/B
- -12.67
- EV/EBITDA
- -0.53
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -2748.16%
- ROIC
- -227.73%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-39,571,000 · 23.75%
- EPS
- $-2.58 · 39.29%
- Op Income
- $-37,714,000
- FCF YoY
- 0.50%
Performance & Tape
- 52W High
- $20.40
- 52W Low
- $1.00
- 50D MA
- $7.17
- 200D MA
- $8.11
- Beta
- 0.60
- Avg Volume
- 9.77K
Get TickerSpark's AI analysis on ANGN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 28, 23 | Nissenson Allen | other | 4,100 |
| Dec 28, 23 | Chudnovsky Yekaterina | other | 4,100 |
| Dec 28, 23 | WILSON KAREN J | other | 4,100 |
| Dec 28, 23 | ADAMS JULIAN | other | 4,100 |
| Dec 28, 23 | Venkatesan Jay | other | 4,100 |
| Dec 28, 23 | Ashe Carol Gail | other | 4,100 |
| Dec 28, 23 | RUFFOLO ROBERT R | other | 4,100 |
| Dec 22, 23 | Chudnovsky Yekaterina | buy | 1,213,000 |
| Jun 1, 23 | Chudnovsky Yekaterina | other | 0 |
| Jun 1, 23 | Chudnovsky Yekaterina | other | 4,525 |
Our ANGN Coverage
We haven't published any research on ANGN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ANGN Report →